Indication

Prostate adenocarcinoma with neuroendocrine differentiation

1 clinical trial

2 products

Clinical trial

A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2023-03-14

Product

Product